Gan & Lee Pharmaceuticals.

SHSE:603087 Stock Report

Market Cap: CN¥27.7b

Gan & Lee Pharmaceuticals Future Growth

Future criteria checks 5/6

Gan & Lee Pharmaceuticals is forecast to grow earnings and revenue by 43.2% and 27.4% per annum respectively. EPS is expected to grow by 42.8% per annum. Return on equity is forecast to be 10.9% in 3 years.

Key information

43.2%

Earnings growth rate

42.8%

EPS growth rate

Biotechs earnings growth43.6%
Revenue growth rate27.4%
Future return on equity10.9%
Analyst coverage

Low

Last updated29 Oct 2024

Recent future growth updates

Recent updates

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Sep 04
Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Apr 29
Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Mar 01
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Earnings and Revenue Growth Forecasts

SHSE:603087 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,5121,524N/A1,4924
12/31/20254,5421,166N/A1,1284
12/31/20243,406680N/A7523
9/30/20242,947581151652N/A
6/30/20242,693505-309234N/A
3/31/20242,610387-344207N/A
12/31/20232,608340-444109N/A
9/30/20232,381241-859-241N/A
6/30/20232,107-108-795-43N/A
3/31/20231,580-504-92047N/A
12/31/20221,712-440-687297N/A
9/30/20222,346168-108757N/A
6/30/20222,971882156913N/A
3/31/20223,7531,3764901,102N/A
12/31/20213,6121,4533861,078N/A
9/30/20213,6731,4163201,047N/A
6/30/20213,6301,2963211,067N/A
3/31/20213,4411,2984431,216N/A
12/31/20203,3621,2316591,241N/A
9/30/20203,2341,1928241,318N/A
6/30/20203,1441,2079961,401N/A
3/31/20202,9371,1938041,103N/A
12/31/20192,8951,1677511,158N/A
12/31/20182,387934-95418N/A
12/31/20172,3711,080N/A950N/A
12/31/20161,771770N/A686N/A
12/31/20151,220447N/A502N/A
12/31/2014927305N/A296N/A
12/31/2013693205N/A167N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603087's forecast earnings growth (43.2% per year) is above the savings rate (2.8%).

Earnings vs Market: 603087's earnings (43.2% per year) are forecast to grow faster than the CN market (26% per year).

High Growth Earnings: 603087's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603087's revenue (27.4% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 603087's revenue (27.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603087's Return on Equity is forecast to be low in 3 years time (10.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y